

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Guangzhou Innogen Pharmaceutical Group Co., Ltd.**

**廣州銀諾醫藥集團股份有限公司**

*(A joint stock company established in the People's Republic of China with limited liability)*

**(Stock Code: 2591)**

**VOLUNTARY ANNOUNCEMENT  
INCLUSION IN THE STOCK LIST OF  
THE SHANGHAI-HONG KONG STOCK CONNECT AND  
THE SHENZHEN-HONG KONG STOCK CONNECT**

This announcement is made by Guangzhou Innogen Pharmaceutical Group Co., Ltd. (the **“Company”**), together with its subsidiaries the **“Group”**) on a voluntary basis to inform the shareholders of the Company (the **“Shareholders”**) and potential investors of its recent updates.

The board (the **“Board”**) of directors (the **“Directors”**) of the Company is pleased to announce that the H shares of the Company (**“H Shares”**) are included in the list of eligible securities under the Shanghai-Hong Kong Stock Connect and the Shenzhen-Hong Kong Stock Connect programs (the **“Stock Connect Programs”**) with effect from 8 December 2025, pursuant to the announcements made by the Shanghai Stock Exchange and the Shenzhen Stock Exchange, respectively.

The inclusion of the H Shares under the Stock Connect Programs allows eligible investors in the Chinese Mainland to directly invest in the H Shares via the Shanghai Stock Exchange and the Shenzhen Stock Exchange. The Board believes that the inclusion in the Stock Connect Programs will further expand the Company's investor base and increase the trading liquidity of the H Shares, thereby enhancing the investment value of the H Shares and reputation of the Company in the capital market.

**Information on the Stock Connect Programs**

The Shanghai-Hong Kong Stock Connect and the Shenzhen-Hong Kong Stock Connect are stock market trading mechanisms which allow interconnectivity and mutual access. The Shanghai Stock Exchange, the Shenzhen Stock Exchange and The Stock Exchange of Hong Kong Limited have established technical connectivity to enable investors in the Chinese Mainland and the Hong Kong Special Administrative Region of the People's Republic of China to trade eligible stocks listed on each other's stock exchange through their local securities firms or brokers.

The Company would like to thank the Shareholders and investors for their continued support. The Company will continue to strive to develop its business and create value for the Shareholders.

**Shareholders and potential investors are advised to exercise caution when dealing in the securities of the Company.**

By order of the Board  
**Guangzhou Innogen Pharmaceutical Group Co., Ltd.**  
**Dr. WANG QINGHUA**  
*Chairman of the Board*

Shanghai, the People's Republic of China, 8 December 2025

*As at the date of this announcement, the Board comprises Dr. WANG QINGHUA, Ms. Jiang Fan, Ms. Xu Wenjie and Mr. Huang Bing as executive Directors; Mr. HO KYUNG SHIK and Mr. Heng Lei as non-executive Directors; and Mr. Tao Wuping, Dr. Song Ruilin and Mr. Chan Heung Wing Anthony as independent non-executive Directors.*